2023年4月27至28日，2023第八届疫苗中国领导者年会在上海顺利召开，博沃生物CEO吴克博士受邀出席大会，主持专场“技术为核——新型疫苗技术创新与突破”和圆桌会议“疫苗行业技术创新之路探讨”，并做主题演讲“新型疫苗技术路径应用研究”。
请上下滑动观看
本次大会以“聚焦创新，放眼未来”为主题，深度聚焦疫苗全产业链的创新生产与国际化进程。邀请了众多行业大咖、学者和企业家出席，共同探讨疫苗产业的未来发展趋势和市场前景。
作为人用疫苗领域以创新为导向的高新技术企业，博沃生物始终致力于促进新型疫苗的推广和成果的全球化，力争成为全球疫苗高端制造商与供应商。博沃生物将在人用疫苗领域的道路上坚守初心、无畏险阻、砥砺前行，实现我们“为生命喝彩”的使命！
On April 27th to 28th , 2023, the "2023 VAC China (The 8th Vaccine China Leaders Annual Meeting 2023)" was held in Shanghai, China. Dr. Wu Ke, CEO of BravoBio, was invited to the Meeting as chairman of the Session "Technology is essential - Innovation and breakthrough of new vaccine technology" and the Panel "Discussion on vaccine industry’s technological innovation", as well as gave a keynote speech on "Research on application of new vaccine technology development".
Under the theme of "Focus on Innovation, See the Future", the Meeting focused on the innovative production of vaccine industry and its internationalization progress. KOLs, academicians and entrepreneurs from vaccine industry were invited to the Meeting, and shared their insightful views on future development and market prospect of vaccine industry.
As an innovation-driven vaccine company, BravoBio is dedicated to promoting its achievements in novel vaccines globally, and making the company one of the high-end vaccines manufacturers and suppliers. In this course, BravoBio will stick to its original intention, brave dangers and forge ahead, endeavoring to realize our mission of "Cheers to life"!
关于博沃生物
上海博沃生物科技有限公司（简称博沃生物）2011年3月成立于上海张江高科技园区，2021年10月迁至北上海生物医药园。2012年12月设立了武汉博沃，是国家级高新技术企业、中国疫苗行业协会理事单位。2020年公司被德勤Deloitte评为“中国明日之星”，是内地唯一获奖的生物医药企业。公司具有基因编辑/构建/克隆/检测、细菌大规模培养、细胞/病毒大规模培养、生物活性物质制备（多糖、蛋白质、病毒等）、多糖与蛋白质化学结合、新型佐剂、新型制剂、新型检测等多个先进技术平台，满足各类创新型生物医药特别是疫苗开发的需要。博沃生物以满足中国和世界人民健康生活的美好愿景为己任，致力于通过重磅级创新疫苗的开发和市场化运营，成为全球疾病控制领域的主力军。
Shanghai BravoBio Co., Ltd (BravoBio) was established in Zhangjiang Hi-Tech Park in Shanghai in March 2011 and moved to MediPark in North Shanghai in October 2021. Its subsidiary company, Wuhan BravoVax Co., Ltd (BravoVax), was founded in December 2012. BravoVax is a "state level high-tech enterprise" and a council member of China Association of Vaccines (CAV). It was awarded as "China Rising Star" by Deloitte in 2020, becoming the only biopharmaceutical enterprise in Chinese mainland to win this award. The company boasts a number of advanced technology platforms, including gene editing / construction / cloning / detection, large-scale bacterial / cell / virus culture, preparation of bioactive substances (polysaccharide, protein, virus, etc.), chemical combination of polysaccharide and protein, novel adjuvant, new preparation and analytical assays, etc. to meet the needs of developing innovative biologics, especially vaccines. BravoBio has held the mission to improve the quality of people's lives, aiming for a healthier and happier future. The company is active to be a global supplier of high-quality vaccine through development and commercialization of its innovative and blockbuster vaccines, contributing to the control of global diseases.
关注博沃生物
